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• Malignant pleural mesothelioma (MPM) is a disease with a long latency period and a dismal prognosis. Early diagnosis of MPM can 
improve patients’ outcome but is hampered by non-specific symptoms and investigations, which delay diagnosis and result in 
advanced stage disease [van Meerbeeck JP, 2011]. An accurate non-invasive test allowing early stage diagnosis in asbestos-exposed 
persons is currently lacking and blood biomarkers have not proven to be useful. 
 
• Breathomics aims at a non-invasive analysis of volatile organic compounds (VOCs) in breath reflecting the cells’ metabolism. Recently, 
it was possible to discriminate MPM from controls using an electronic nose [Chapman EA 2009, Dragonieri S 2011]. However, the 
breathogram of MPM obtained by this eNose does not allow identification of MPM-related VOCs. Ion mobility spectrometry (IMS) 
combines the advantages of online direct sampling with the possibility of VOC identification and linking to MPM pathogenesis 
[Baumbach JI 2009].  
 
• With a non-targeted approach, we investigated which VOCs could play a role in MPM pathogenesis in order to build a possible 
diagnostic MPM tool using IMS. 
• Participants: 10 MPM patients, 10 healthy asbestos-exposed individuals (mean asbestos fiber year count 14,6 (5,5) fibre.years/cc) and 
10 healthy non-exposed individuals were included after refraining from eating, drinking and smoking for at least 2 hours before 
sampling.  
 
• Breath sampling: Subjects breathed tidally with a nose clip for 3 minutes through a mouthpiece connected to a bacteria filter. Ten ml 
alveolar air was sampled via a CO2-controlled ultrasonic sensor and subsequently analyzed using the BioScout Multicapillary 
Column/Ion Mobility Spectrometer (MCC/IMS, B&S Analytik, Dortmund, Germany, Figure 2) [Westhoff M 2009], by using N2 as a carrier 
and drift gas. Per subject a background sample was taken to correct for contamination.  
 
• Breath analysis: Preprocessing of the data was done by base correction, normalization to the reactant ion peak (RIP), compensating 
RIP-tailing and smoothening techniques. Peaks of interest were visually selected in breath and background samples and their intensity 
(V) was analyzed and compared via on-board VisualNow 3.2 software and SPSS v21 (IBM) using Mann-Whitney-U tests. Further 
selection of interesting peaks was done by looking at the alveolar gradient. MPM diagnostic accuracy was obtained by ROC-analysis. 
• Several VOCs of interest were derived from the breath according to the alveolar gradient. Four peaks (P12, P16, P24 and P36) had a 
significant effect in discriminating MPM patients from controls. Only P12 and P24 have a relevant AUCROC to positively diagnose MPM. 
• The intensity of P12 was found to be significantly higher in MPM patients. Hence, this could be linked to MPM development and serve 
as an early diagnostic marker for MPM. P24 was significantly lower in non-exposed persons and could serve as a marker for asbestos-
exposure. 
• GC-MS analysis and further large cohort studies including healthy unexposed individuals are ongoing in order to validate the accuracy of 
IMS as a diagnostic tool for MPM. Results need to be validated in an independent test set. 
Table 1: Baseline characteristics. Table 2: VOC peak comparison. 
Figure 3: VOC peak 
visualization in the 
breath of an MPM 
patient (upper), an 
asbestos-exposed 
individual (middle) 
and a healthy non-
exposed individual 
(lower).  
RT:  retention time. 
1/K0: inverse 
reduced ion 
mobility. 
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Figure 4: ROC curves displaying the 
diagnostic accuracy of four selected peaks in 
discriminating MPM patients from asbestos-
exposed and non-exposed controls. 
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MPM  
Patients 
AEx 
Individuals 
Healthy 
Individuals 
p-value 
N 10 10 10 
Gender (Male/Female) 8/2 9/1 8/2 1,00a 
Age (year)b 65,0 (59,0 – 67,0) 55,0 (54,0 – 56,0) 55,5 (49,0 – 61,0) <0,01 
Weight (kg)c 73,0 (11,8) 84,1 (12,7) 79,2 (9,8) 0,12 
Length (m)c 1,73 (0,06) 1,77 (0,06) 1,77 (0,08) 0,33 
BMI (kg/m²)c 24,3 (3,6) 26,9 (3,6) 25,1 (2,1) 0,20 
Smoking status (current/ex/non) 3/3/4 3/4/3 1/0/9 0,05a 
aFisher’s exact test, bMedian (IQR), cMean (SD). AEx: Asbestos-exposed. MPM: Malignant Pleural 
Mesothelioma. 
Peak 
MPM 
Intensity (V)* 
AEx 
Intensity (V)* 
Healthy 
Intensity (V)* 
p-value 
Between 
group 
significancea 
AUCROC 
P6 0,001 [-0,008 – 0,006] 0,010 [-0,011 – 0,022] 0,082 [0,049 – 0,168] <0,01 †, # 0,300 
P9 0,087 [0,045 – 0,111] 0,102 [0,088 – 0,138] 0,011 [-0,018 – 0,025] <0,01 †, # 0,565 
P11 0,050 [0,025 – 0,058] 0,045 [0,032 – 0,054] 0,056 [0,045 – 0,071] 0,35 0,450 
P12 0,043 [0,024 – 0,077] 0,015 [0,011 – 0,022] 0,002 [-0,001 – 0,003] <0,01 ‡, † 0,865 
P16 -0,006 [-0,012 – -0,001] -0,003 [-0,006 – 0,003] 0,003 [-0,001 – 0,028] 0,03 † 0,235 
P19 0,021 [0,007 – 0,023] 0,034 [0,017 – 0,041] 0,031 [0,007 – 0,044] 0,63 0,350 
P20 0,023 [0,004 – 0,044] 0,047 [0,022 – 0,069] -0,002 [-0,009 – 0,005] 0,01 †, # 0,555 
P24 0,058 [0,031 – 0,089] 0,037 [0,013 – 0,067] -0,003 [-0,015 – 0,026] 0,01 †, # 0,770 
P26 0,000 [-0,002 – 0,007] 0,005 [-0,002 – 0,009] 0,008 [0,001 – 0,024] 0,33 0,355 
P27 0,002 [-0,002 – 0,010] 0,011 [-0,002 – 0,044] 0,009 [0,001 – 0,014] 0,47 0,360 
P28 0,002 [0,001 – 0,015] 0,001 [0,000 – 0,003] 0,000 [-0,001 – 0,002] 0,29 0,670 
P31 0,008 [0,000 – 0,022] 0,020 [-0,016 – 0,036] 0,007 [-0,016 – 0,013] 0,46 0,515 
P36 -0,001 [-0,010 – 0,001] 0,004 [-0,006 – 0,013] 0,018 [0,002 – 0,038] 0,05 † 0,265 
P37 0,005 [0,003 – 0,010]  0,002 [-0,014 – 0,004] 0,029 [0,007 – 0,039] <0,01 ‡, †, # 0,515 
*Median [IQR]. 1/K0: inversed reduced ion mobility. AEx: healthy asbestos exposed individual. AUCROC: Area under the 
receiver operator characteristic curve (accuracy in diagnosing MPM). MPM: Malignant Pleural Mesothelioma patient. RT: 
retention time. ap<0,05 for MPM vs. AEx (‡), MPM vs. Healthy (†) and  AEx vs. Healthy (#). 
Figure 1: Alveolar gradient  of selected peaks (peak intensity in breath – 
peak intensity in background samples; here shown as means). 
Figure 2: The MCC/IMS device 
(BioScout) with sampling unit 
(SpiroScout). 
• Malignant pleural mesothelioma (MPM) is a disease with 
a long latency period and a dismal prognosis. Early 
diagnosis of MPM can improve patients’ outcome but is 
hampered by non-specific symptoms and investigations, 
which delay diagnosis and result in advanced stage 
disease [van Meerbeeck JP, 2011]. An accurate non-
invasive test allowing early stage diagnosis in asbestos-
exposed persons is currently lacking and blood 
biomarkers have not proven to be useful. 
 
• Breathomics aims at a non-invasive analysis of volatile 
organic compounds (VOCs) in breath reflecting the cells’ 
metabolism. Recently, it was possible to discriminate 
MPM from controls using an electronic nose [Chapman 
EA 2009, Dragonieri S 2011]. However, the breathogram 
of MPM obtained by this eNose does not allow 
identification of MPM-related VOCs. Ion mobility 
spectrometry (IMS) combines the advantages of online 
direct sampling with the possibility of VOC identification 
and linking to MPM pathogenesis [Baumbach JI 2009].  
 
• With a non-targeted approach, we investigated which 
VOCs could play a role in MPM pathogenesis in order to 
build a possible diagnostic MPM tool using IMS. 
• Participants: 10 MPM patients, 10 healthy asbestos-
exposed individuals (mean asbestos fiber year count 14,6 
(5,5) fibre.years/cc) and 10 healthy non-exposed 
individuals were included after refraining from eating, 
drinking and smoking for at least 2 hours before sampling.  
 
• Breath sampling: Subjects breathed tidally with a nose 
clip for 3 minutes through a mouthpiece connected to a 
bacteria filter. Ten ml alveolar air was sampled via a CO2-
controlled ultrasonic sensor and analyzed using the 
BioScout Multicapillary Column/Ion Mobility 
Spectrometer (MCC/IMS, B&S Analytik, Dortmund, 
Germany, Figure 2) [Westhoff M 2009], by using N2 as a 
carrier and drift gas. Per subject a background sample was 
taken to correct for contamination.  
 
• Breath analysis: Preprocessing of the data was done by 
base correction, normalization to the reactant ion peak 
(RIP), compensating RIP-tailing and smoothening 
techniques. Peaks of interest were visually selected in 
breath and background samples and their intensity (V) 
was analyzed and compared via on-board VisualNow 3.2 
software and SPSS v21 (IBM) using Mann-Whitney-U 
tests. Further selection of interesting peaks was done by 
looking at the alveolar gradient. 
• Several VOCs of interest were derived from the breath 
according to the alveolar gradient. Four peaks (P12, P16, 
P24 and P36) were discriminating MPM patients from 
controls with only P12 and P24 having a relevant AUCROC. 
• The intensity of P12 was found to be significantly higher in 
MPM patients. Hence, this could be linked to MPM 
development and serve as an early diagnostic marker for 
MPM. P24 could serve as a marker for asbestos-exposure. 
• GC-MS analysis and further large cohort studies including 
healthy unexposed individuals are ongoing in order to 
validate the accuracy of IMS as a diagnostic tool for MPM. 
Results need to be validated in an independent test set. 
Results 
Peak 
  
MPM 
Intensity (V)* 
AEx 
Intensity (V)* 
p-value AUCROC 
P6 0,018 [0,013 – 0,027] 0,026 [0,019 – 0,031] 0,41 0,490 
P9 0,106 [0,085 – 0,124] 0,116 [0,104 – 0,145] 0,17 0,763 
P11 0,089 [0,068 – 0,120] 0,082 [0,064 – 0,093] 0,45 0,750 
P12 0,078 [0,054 – 0,168] 0,027 [0,022 – 0,060] <0,01 0,877 
P19 0,044 [0,038 – 0,048] 0,045 [0,042 – 0,055] 0,76 0,777 
P20 0,044 [0,029 – 0,059] 0,072 [0,043 – 0,078] 0,17 0,620 
P24 0,102 [0,085 – 0,123] 0,079 [0,069 – 0,089] 0,03 0,863 
P26 0,010 [0,007 – 0,016] 0,011 [0,006 – 0,013] 0,76 0,567 
P27 0,012 [0,008 – 0,021] 0,013 [0,010 – 0,052] 0,60 0,618 
P33 0,006 [0,004 – 0,007] 0,010 [0,007 – 0,019] 0,03 0,237 
P36 0,012 [0,009 – 0,016] 0,012 [0,009 – 0,016] 0,82 0,517 
*Median [IQR]. 1/K0: inversed reduced ion mobility. AEx: healthy asbestos exposed individual. AUCROC: 
Area under the receiver operator characteristic curve (accuracy in diagnosing MPM). MPM: Malignant 
Pleural Mesothelioma patient. RT: retention time. 
MPM Patients Asbestos-Exposed Individuals P-value 
N 10 10 
Gender (Male/Female) 8/2 9/1 1,00a 
Age (year)b 65,0 (59,0 – 67,0) 55,0 (54,0 – 56,0) <0,01 
Weight (kg)c 73,0 (11,8) 84,1 (12,7) 0,06 
Length (m)c 1,7 (0,06) 1,8 (0,06) 0,21 
BMI (kg/m²)c 24,3 (3,6) 26,9 (3,6) 0,13 
Smoking status (current/ex/non) 3/3/4 3/4/3 0,87a 
CO (ppm)b 2,5 (2,0 – 5,0) 4,0 (2,0 – 13,0) 0,14 
COHb (%)b 1,1 (1,0 – 1,4) 1,3 (1,0 – 2,7) 0,14 
FeNO (ppb)c 19,8 (9,7) 20,2 (10,0) 0,94 
aFisher’s exact test 
bMedian (IQR) 
cMean (SD) 
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